[pubmed] Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
Posté : 28 juin 2021 12:00
Cureus. 2021 May 22;13(5):e15174. doi: 10.7759/cureus.15174.
ABSTRACT
Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we describe the case of a 65-year-old male with metastatic renal cell carcinoma on pembrolizumab diagnosed with new-onset seronegative myasthenia gravis and review literature on its management.
PMID:34178496 | PMC:PMC8216640 | DOI:10.7759/cureus.15174
Source: https://pubmed.ncbi.nlm.nih.gov/3417849 ... 3&v=2.14.4